Silver linings and striving for gold
Jenny Ousbey, founder of OVID Health, on raising the bar for patient-centricity
Welcome to the patient-centricity special! Articles in this issue shine a light on how pharma is making strides in developing meaningful and impactful patient partnerships, but also highlight that much more can be done to ensure that patients remain centre stage going forward.
We’re also thrilled to announce alongside partner OVID Health the results of the first ever Patient Partnership
Index 2020. Turn to page 14 for OVID Health founder Jenny Ousbey’s thoughts on the concept behind the Index, how we hope it will raise the bar for patient-centricity and advocacy going forward, and how the entering companies fared.
On the same theme, on page 20 John Pinching discusses with five panellists the rise of Patient 2.0 and how pharma is successfully leveraging their experience and expertise to ensure the patient voice is represented at all levels.
Elsewhere, Roche’s Michael Goetzl looks at global variations in the approach to managing diabetes, and the potential lessons for the UK (p28), while Wilmington Healthcare’s Oli Hudson explores how the coronavirus pandemic is changing pharma’s relationship with the NHS in the recovery era (p32).
Finally, a reminder that the deadline for entering PharmaTimes Marketer of the Year, PharmaTimes Communications Team of the Year and the Sales Awards 2020 is nearing, so if you’re thinking of taking part don’t delay. Also, both International and the US Clinical Researcher of the Year competitions are progressing with finals days to be held virtually for the first time in response to the coronavirus pandemic (visit www.pharmatimes.com/competitions for more information).
Jenny Ousbey, founder of OVID Health, on raising the bar for patient-centricity
Interest in our own health has grown exponentially in recent decades and COVID-19 has continued to highlight the increasing currency of disease knowledge. Our five panelists discuss the rise of Patient 2.0 and how pharma is successfully leveraging their experience and expertise
Roche’s Michael Goetzl looks at global variations in the approach to managing diabetes, and the potential lessons for the UK
Oli Hudson, content director at Wilmington Healthcare, explores how the coronavirus pandemic is changing pharma’s relationship with the NHS
Janssen's Joaquín Casariego says pharma can do more to ensure patients are truly front and centre
Charlotte Walker-Osborn considers whether the law will be able to keep up with the rise of robots, drones and automated processes
Joseph Saba considers the affect of COVID-19 on access to healthcare
Peter Impey, Managing Director, 90TEN Communications – part of the Envision Pharma group
Gareth Powell, Patient Engagement Project Lead, National Institute for Health Research (NIHR)
Henry Featherstone, Director of Public Affairs, Sanofi